Pharmaceutical Investing Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
Pharmaceutical Investing Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate
Juggernaut Increases Oversubscribed Financing to $8,600,000 due to Strong Demand from Institutions and Accredited Investors
